Sign in
Not yet taking people in AustriaPhase 4

Landiolol given early to people having a heart attack with ST elevation

Tests landiolol, given early, in adults with ST-elevation heart attack needing a procedure.

Key facts

Who runs it
Medical University Of Vienna
Where
Vienna, AustriaSee the site
Registry title
The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention – A prospective, randomized, double-blinded, placebo-controlled, phase IV pilot trial (STEMILAND-1)
Status
Not yet recruiting
Phase
Phase 4
People taking part
60 people, planned
Started
7 Jan 2026
Expected to end
1 Jun 2027
Type of study
Interventional
Record updated
16 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a heart attack of the front or side wall of the heart (ST-elevation acute coronary syndrome) who are treated at the study center. They must be stable and have a heart rate above 70 per minute.

Age
18 years or older
Sex
All sexes can join
Disease stage
Anterior or lateral ST-elevation acute coronary syndrome, with ST-segment elevation in two or more of the chest leads V1-V6, and I and aVL. Hemodynamically stable (MAP >60 mmHg, heart rate > 70/min).

Main reasons for not taking part

  • Known or suspected pregnancy
  • Acute asthma exacerbation
  • Acute heart failure or cardiogenic shock (Killip Classes III and IV)
  • Known problems of the heart's electrical conduction system (e.g., sick-sinus-syndrome, AV-block II° or III°)
  • Allergy or insensitivity to ß-blockers

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Anterior or lateral ST-elevation acute coronary syndrome (STE-ACS; defined as ST-segment elevation in two or more of precordial leads V1-V6, and I and aVL, representing anterior wall infarction or ischemia)
  • Treated at our study center
  • Age >= 18 years
  • Hemodynamically stable (MAP >60 mmHg, heart rate > 70/min)
  • Oral and written informed consent

Who cannot take part

  • Known pathologies of the cardiac electrical conduction system (e.g., sick-sinus-syndrome, AV-block II° or III°)
  • Acute heart failure and cardiogenic Shock (Killip Classes III and IV)
  • Allergy or insensitivity to ß-blockers
  • Known pulmonary hypertension
  • Heart rate < 50 bpm
  • Known or suspected pregnancy
  • Acute asthma exacerbation
  • Severe metabolic acidosis
  • Known pheochromocytoma
  • Anticipated time to wire-crossing >120 minutes after first medical contact
  • Thrombolysis candidate as defined by treating physician

Where in Austria

  • Klinik LandstrasseVienna, AustriaNot yet recruiting

About the trial

What the trial wants to find out

The primary objective is to evaluate the feasibility of very early continuous i.v. administration of the highly cardioselective betablocker Landiolol in anterior/lateral ST-elevation acute coronary syndrome (STE-ACS).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention – A prospective, randomized, double- blinded, placebo controlled, phase IV pilot trial (STEMILAND-1)
Plain-language title
Landiolol given early to people having a heart attack with ST elevationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
16 September 2026